Dear colleagues,
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B-cell lymphoma (R/R LBCL) and R/R multiple myeloma, and is rapidly being introduced to other disease fields.
Thrombosis and bleeding complications are increasingly reported in patients undergoing CAR T-cell therapy, affecting an estimated 10–20% of patients. However, their incidence and risk factors remain unclear, also due to heterogeneity between reporting studies and missing data, causing these complications to remain under-recognized and poorly understood.
Current supportive care practices are largely extrapolated from stem cell transplant populations, despite CAR T-cell therapy’s distinct pathophysiology, and there is no consensus on optimal monitoring intervals, transfusion thresholds, or preventive interventions.
Hence, to gain a better understanding of current practices in supportive care management for CAR T-cell patients, particularly in the hemostasis-related monitoring and supportive care, as well as how complications of thrombosis and bleeding in patients receiving CAR T-cell therapy are documented, we please ask you to complete the following survey: https://redcap.link/support_CART
Please feel free to distribute this survey among colleagues involved in CAR T-cell therapy, hemostasis and thrombosis, and/or transfusion medicine.
Thank you in advance for your contributions and collaboration.
On behalf of the ISTH SSC Cancer-associated thrombosis and hemostasis and EHA SWG on Transfusion,
Mandy Lauw, Darko Antic, Lizzie Jutchinson, Kirsty Sharplin, Simon Stanworth